Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2023 | Fragmentomic analysis of a ctDNA discriminates ER status in metastatic breast cancer

Marina N. Sharifi • 7 Dec 2023
SABCS 2023
Breast Cancer

Marina N. Sharifi, MD, University of Wisconsin Carbone Cancer Center, Madison, WI, tells us more about a study using fragmentomic analyses of circulating tumor DNA to discriminate estrogen-receptor positive status in patients with metastatic breast cancer. The study showed for the first time that sequencing from standard targeted ctDNA panels can be utilized to infer phenotypic information through analysis of ctDNA fragmentation patterns in patients with metastatic breast cancer. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Marina N. Sharifi

Progress in ctDNA research: advancements in early-stage breast cancer detection
0:35
Progress in ctDNA research: advancements in early-stage breast cancer detection
Marina N. Sharifi • 7 Dec 2023
Advancing precision medicine: cell-free DNA fragment omics in metastatic HER2-negative breast cancer
0:47
Advancing precision medicine: cell-free DNA fragment omics in metastatic HER2-negative breast cancer
Marina N. Sharifi • 7 Dec 2023
Potential applications of ctDNA fragmentation patterns in HER2- BC
0:38
Potential applications of ctDNA fragmentation patterns in HER2- BC
Marina N. Sharifi • 7 Dec 2023

Related Videos

Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
1:20
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
Sarbajit Mukherjee • 1 Jun 2026
CRCI and compromised adjuvant chemotherapy delivery in cancer
5:16
CRCI and compromised adjuvant chemotherapy delivery in cancer
Filippos Koinis • 1 Jun 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
The content of VJOncology is intended for healthcare professionals